

Generic Contrast Agents

Our portfolio is growing to serve you better. Now you have a choice.



[VIEW CATALOG](#)

AJNR

Intrathecal Gadolinium: Its Time Has Come?

W.P. Dillon

AJNR Am J Neuroradiol 2008, 29 (1) 3-4

doi: <https://doi.org/10.3174/ajnr.A0884>

<http://www.ajnr.org/content/29/1/3>

This information is current as
of May 10, 2025.

evaluation with cerebrospinal fluid flow measurements at MR imaging. *Radiology* 1996;198:523–29

8. Bradley WG, Whittemore AR, Watanabe AS, et al. Association of deep white matter infarction with chronic communicating hydrocephalus: implications regarding the possible origin of normal pressure hydrocephalus. *AJNR Am J Neuroradiol* 1991;12:31–39
9. Bradley WG, Bahl G, Alksne JF, et al. Idiopathic normal pressure hydrocephalus may be a “two hit” disease: benign external hydrocephalus in infancy followed by deep white matter ischemia in late adulthood. *J Magn Reson Imaging* 2006;24:747–55
10. Marshall VG, Bradley WG, Marshall CE, et al. Deep white matter infarction: correlation of MR imaging and histopathologic findings. *Radiology* 1988;167:517–22
11. Bradley WG, Safar FG, Furtado C, et al. Increased intracranial volume: a clue to the etiology of idiopathic normal-pressure hydrocephalus? *AJNR Am J Neuroradiol* 2004;25:1479–84

W.G. Bradley, Jr

Professor and Chair

Department of Radiology

University of California, San Diego

DOI 10.3174/ajnr.A0867

EDITORIAL

Intrathecal Gadolinium: Its Time Has Come?

The article in this month's *American Journal of Neuroradiology* by Albayram et al (“Gadolinium-Enhanced MR Cisternography to Evaluate Dural Leaks in Intracranial Hypotension Syndrome”) ¹ reviews the authors' experience with intrathecal gadolinium administration for the detection of CSF fistulas resulting in spontaneous intracranial hypotension (SIH). In their report, the authors reviewed 19 patients with clinical SIH in whom 0.5 mL of gadopentetate dimeglumine diluted with 4 mL of saline was instilled intrathecally 1 hour before fat-suppressed T1-weighted MR imaging. They found CSF fistulas in 17 of 19 patients; 14 of the fistulas were subsequently confirmed, but in 3, the exact site of the fistula was not identified due to the gross extent of leakage by the time the MR imaging was performed. Ten patients had a single fistula, whereas 4 patients had multiple fistulas (2 tears in 3 patients and multiple tears in 1 patient). Of importance, 4 patients, all with meningeal diverticula, showed only paravertebral leakage without prominent epidural leakage. Although the authors did not routinely compare intrathecal MR myelography with CT cisternography, 2 patients did have both studies, and 1 of these showed leakage along a nerve root on MR myelography that was not visible by using CT myelography. Clinically, no patients were found to have an untoward reaction, behavioral changes, or evidence of toxicity at 24 hours and at 6–12 months following the examination.

Di Chiro et al ² first used intrathecal gadolinium to detect intracranial CSF fistulas in Beagle dogs (Beagles apparently have spontaneous CSF rhinorrhea). Using gadolinium MR cisternography, they identified fistulas in 2 dogs that had been previously found to have CSF rhinorrhea by radioisotope cisternography. In 1999, Jinkins et al ³ administered cisternal gadolinium to rabbits, showing no behavioral effects, good cisternal contrast, but “gradual diffusion of the gadolinium into the cranial parenchyma . . . on the delayed

MR studies (45 minutes–6 hours), as revealed by progressive generalized enhancement of the brain.” Zeng et al ⁴ from the same group, first piloted the technique in humans, showing excellent opacification and no gross behavioral changes following the instillation of 0.2 mL, 0.5 mL, or 1 mL of gadopentetate dimeglumine (500 mmol/L) diluted in 5 mL of CSF. Although long-term safety studies have yet to be performed, histologic studies in animals have shown no changes concerning acute toxicity of intrathecal gadolinium, and a recent international registry study of 95 humans reported no significant toxicity of 0.5–1 mL of intrathecally administered gadopentetate dimeglumine. ⁵ Aydin et al ⁶ reported that gadolinium cisternography demonstrated leaks in 2 patients with negative findings on CT cisternography, and Tali et al ⁷ used gadolinium cisternography to determine the communication between the CSF pathways and intracranial arachnoid cysts. Although the spatial resolution of MR imaging is typically less than that achieved by using CT myelography, the lack of ionizing radiation and better contrast resolution are enticing factors that make MR imaging a viable alternative to CT, especially in children and in those in whom subtle or slow leaks are suspected. ⁸

I have personally used gadolinium cisternography in several patients with SIH who had difficult-to-detect spinal fistulas. After obtaining informed consent from the patients, I diluted 0.5 mL of gadopentetate dimeglumine with 5 mL of iohexol (Omnipaque 180; GE Healthcare, Piscataway, NJ) and slowly injected this mixture intrathecally during a 3-minute period. The patients tolerated this procedure well and had no immediate or subacute side effects, and the technique allowed me to study the patients first with CT myelography, followed by MR myelography. Radioisotopes could also be administered at the same time by using a single spinal puncture.

Obviously gadolinium cisternography brings up concerns regarding the safety of the intrathecal use of gadolinium-based contrast agents. The intrathecal use of gadolinium is not currently FDA-approved. The off-label use of these compounds should be considered carefully and used only in patients with normal renal function and CSF clearance in whom currently accepted techniques for detecting CSF dynamics or leaks are either unrevealing or associated with unacceptable potential consequences or risks. Central nervous system (CNS) toxicity following the intravenous use of gadolinium in a patient with renal failure has been reported. ⁹ In addition, Morris and Miller ¹⁰ reported that the increased signal intensity in the subarachnoid space detected on fluid-attenuated inversion recovery imaging of the brain in patients following previous intravenous gadolinium injections is secondary to contrast agent crossing the intact blood-brain barrier in both healthy patients as well as those with renal failure. There are, no doubt, differences in the CSF clearance among the various compounds as well among patients with various renal clearances, ages, and underlying CNS disorders. The direct enhancement of brain as observed in rabbits by Jinkins ³ (see above) is also a concern that the brain is at risk for toxicity if CSF clearance is impaired or an improper dose is administered. These questions must obviously be addressed before general use of these agents intrathecally.

All that said, gadolinium MR myelography and cisternography may potentially better evaluate obstruction of the sub-

arachnoid space, arachnoid cysts, spontaneous or traumatic intracranial and spinal CSF fistulas, and CSF dynamics. The lack of ionizing radiation, availability of multiplanar views, and the potential to assess dynamics of CSF over time without concern for radiation are appealing aspects of MR imaging-based techniques. However, as we have learned only too clearly from the recent data on nephrogenic systemic sclerosis and its association with gadolinium contrast agents in patients with renal impairment, additional animal and human studies must be performed to further evaluate the long-term safety as well as to prove the clinical efficacy of this procedure in a larger number of human subjects.¹¹ Because the elimination of gadolinium from the CSF compartment has different kinetics than that administered intravenously, the lack of brain and spinal toxicity over the long term must be established before widespread use of this technique is acceptable. Nonetheless, the potential for increased contrast resolution coupled with reduction in radiation exposure is seductive. Its time may have come.

References

1. Albayram S, Kilic F, Ozer H, et al. **Gadolinium-enhanced MR cisternography to evaluate dural leaks in intracranial hypotension syndrome.** *AJNR Am J Neuroradiol* 2008;29:117–22
2. Di Chiro G, Girton M, Frank J, et al. **Cerebrospinal fluid rhinorrhea: depiction with MR cisternography in dogs.** *Radiology* 1986;160:221–22
3. Jinkins J, Williams R, Xiong L. **Evaluation of gadopentetate dimeglumine magnetic resonance cisternography in an animal model: preliminary report.** *Invest Radiol* 1999;34:156–59
4. Zeng Q, Xiong L, Jinkins J, et al. **Intrathecal gadolinium-enhanced MR myelography and cisternography: a pilot study in human patients.** *AJR Am J Roentgenol* 1999;173:1109–15
5. Tali E, Ercan N, Krumina G, et al. **Intrathecal gadolinium (gadopentetate dimeglumine) enhanced magnetic resonance myelography and cisternography: results of a multicenter study.** *Invest Radiol* 2002;37:152–59
6. Aydin K, Guven K, Sencer S. **MRI cisternography with gadolinium-containing contrast medium: its role, advantages and limitations in the investigation of rhinorrhoea.** *Neuroradiology* 2004;46:75–80. Epub 2003 Nov 13
7. Tali E, Ercan N, Kaymaz M, et al. **Intrathecal gadolinium (gadopentetate dimeglumine)-enhanced MR cisternography used to determine potential communication between the cerebrospinal fluid pathways and intracranial arachnoid cysts.** *Neuroradiology* 2004;46:744–54
8. Muñoz A, Hinojosa J, Esparza J. **Cisternography and ventriculography gadopentate dimeglumine-enhanced MR imaging in pediatric patients: preliminary report.** *AJNR Am J Neuroradiol* 2007;28:889–94
9. Maramattom BV, Manno EM, Wijdicks EFM, et al. **Gadolinium encephalopathy in a patient with renal failure.** *Neurology* 2005;64:1276–78
10. Morris JM, Miller GM. **Increased signal in the subarachnoid space on fluid-attenuated inversion recovery imaging associated with the clearance dynamics of gadolinium chelate: a potential diagnostic pitfall.** *AJNR Am J Neuroradiol* 2007;28:1964–67
11. Chewning RH, Murphy KJ. **Gadolinium-based contrast media and the development of nephrogenic systemic fibrosis in patients with renal insufficiency.** *J Vasc Interv Radiol* 2007;18:331–33

W.P. Dillon, MD
Senior Editor

DOI 10.3174/ajnr.A0884